

Prevalence of Hyperhomocysteinemia in Normal Healthy Thai Subjects

WATTANA LEOWATTANA, M.D.*,
KIERTIJAI BHURIPANYO, M.D.**,

NITHI MAHANONDA, M.D.**,
SASIKANT POKUM, B.Sc.*

Abstract

The concentration of circulating total homocysteine is a sensitive marker of inadequate folate and vitamin B12 status. The elevations of plasma homocysteine concentration are associated with an increased risk of vascular disease. The primary goals of this study were to identify plasma homocysteine concentrations in Thai residents and to test for differences in homocysteine levels among sex and age categories. The authors measured plasma total homocysteine concentrations in 3,345 Shinawatra employees (1,133 males, 2,212 females aged between 20-65 years) by using fluorescence polarization immunoassay (FPIA) method. The mean plasma homocysteine concentrations of males and females were 11.495 and 8.547 $\mu\text{mol/L}$ respectively. Plasma homocysteine concentrations were significantly lower in females than in males ($p < 0.0001$). The age-specific plasma homocysteine levels were lower in females than in males for each group, but the levels of each group was not significantly different both in males and females. When more than 12 $\mu\text{mol/L}$ was used as the cut-off value, it was found that 33.6 per cent of males and 6.69 per cent of females were classified as hyperhomocysteinemia subjects. The authors concluded that the prevalence of hyperhomocysteinemia in Thai males is more common than in females. Further investigation should be done to clarify the association between serum folate, vitamin B12, vitamin B6 concentrations and plasma homocysteine concentration.

Key word : Homocysteine, Folate, Vitamin B12, Prevalence, Hyperhomocysteinemia

LEOWATTANA W, MAHANONDA N,
BHURIPANYO K, POKUM S
J Med Assoc Thai 2001; 84 (Suppl 3): S722-S729

* Department of Clinical Pathology,

** Her Majesty Cardiac Center, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand.

Epidemiological studies have identified moderately raised concentrations of homocysteine as a potentially modifiable risk factor for coronary artery disease(1-5). Hyperhomocysteinemia is a recently recognized risk factor that is independent of major risk factors such as diabetes, hypertension, hypercholesterolemia, and smoking. The prevalence estimates of hyperhomocysteinemia vary between 2-17 per cent in the general population and 9-38 per cent in coronary artery disease patients(6-11). Although the mechanisms by which homocysteine promotes atherothrombosis are unknown, the epidemiological evidence for the association of hyperhomocysteinemia with atherothrombotic disease is strong(12). Evidence to support a direct role for homocysteine in the pathogenesis of vascular disease has emerged from studies showing a dynamic and inverse relationship between plasma homocysteine and vascular endothelial function. Acute hyperhomocysteinemia is associated with rapid-onset vascular endothelial dysfunction, an early manifestation of atherosclerosis(13,14). These observations are consistent with reports of dose and time dependent effects of homocysteine on endothelial cellular function *in vitro*(15,16). These findings suggest that even diet-related increments in plasma homocysteine contribute to the development and progression of atherosclerosis.

The aim of the present study was to establish the prevalence of hyperhomocysteinemia in healthy Thai subjects.

MATERIAL AND METHOD

Subjects

A cluster sampling survey was performed on 3,345 highly educated Shinawatra employees (1,133 males and 2,221 females) who had a high socioeconomic status. Informed consent was obtained from all respondents. This project was approved by the ethic committee, Faculty of Medicine Siriraj Hospital, Mahidol University.

Determination of plasma homocysteine concentration

Blood was drawn from fasted subjects and transferred into EDTA tubes. Plasma was immediately obtained by centrifugation at room temperature for 15 minutes at 3,000 g. Aliquots of plasma

were then transferred to a -80°C freezer within 1 hour of sampling and stored for batch analysis. Plasma total homocysteine, which included the sum of protein-bound and free homocysteine, was measured by fluorescence polarization immunoassay (FPIA) method (Imx, Abbott Thailand). The coefficients of variation within and between days for the assays was ≤ 5 per cent.

Statistical analysis

All results are expressed as the mean and standard derivation (SD). Unpaired *t*-tests were carried out to compare parameters between different groups. StatView (Abacus, USA) statistical packages were used for statistical analysis. The significant *p*-value was < 0.05 .

RESULTS

Plasma total homocysteine concentrations were measured for 3,345 individuals aged ≥ 20 years old. The distribution of participants by age, sex, mean plasma total homocysteine concentrations and standard deviations are presented in Table 1. The age-specific total homocysteine concentrations were lower in females than in males for each age group, but the concentrations of each group were not significantly different between males and females. The authors did not find a pattern of increased concentrations of total homocysteine with age from 20-60 years old. The percentile values of plasma total homocysteine concentrations of males and females are shown in Table 2. The 95th percentiles of the male and female group were 18.750 and 12.500 $\mu\text{mol/L}$ respectively. The percentile-specific total homocysteine concentrations were lower in females than in males for each percentile level. Histograms of plasma total homocysteine concentrations of males and females are displayed in Fig. 1. Box plot of plasma total homocysteine levels of males and females are shown in Fig. 2. The mean of total homocysteine values of males and females were 11.495 and 8.547 $\mu\text{mol/L}$ respectively. Plasma homocysteine concentrations were significantly lower in females than in males ($p < 0.0001$). If 12 $\mu\text{mol/L}$ of plasma homocysteine concentration was used as the cut-off value, 33.36 per cent and 6.69 per cent of males and females were classified as hyperhomocysteinemia (Fig. 3).

Table 1. Means and standard deviation of plasma total homocysteine concentrations by age group and sex.

	Age	Mean	Standard deviation
		μmol/L	
Males	20-25 (n=218)	11.899	5.113
	26-30 (n=384)	11.618	4.373
	31-35 (n=269)	11.377	3.962
	36-40 (n=150)	11.065	3.789
	41-45 (n=63)	10.961	2.642
	46-50 (n=32)	11.321	3.558
	51-55 (n=9)	11.008	1.537
	56-60 (n=8)	12.123	2.819
Females	20-25 (n=493)	8.719	2.453
	26-30 (n=969)	8.544	2.877
	31-35 (n=538)	8.404	2.722
	36-40 (n=140)	8.553	2.574
	41-45 (n=51)	8.419	1.793
	46-50 (n=16)	8.534	2.322
	51-55 (n=2)	8.955	0.841
	56-60 (n=3)	8.737	1.156

Table 2. Percentile values used to define categories of plasma total homocysteine by sex.

	Percentile					
	10th	25th	50th	75th	90th	95th
Males	7.892	9.168	10.700	12.803	15.124	18.750
Females	6.017	6.940	8.140	9.600	11.290	12.500

DISCUSSION

This study presents the first reference information on plasma total homocysteine concentrations in a representative sample of the Thai population. The results established that total homocysteine concentrations were not different across age groups from 20 to 60 years old, and were significantly higher in males than in females. The sex differences are consistent with observations from other studies(17-23). The Hordaland Homocysteine Study examined 7,591 males and 8,585 females aged 40-67 years with no history of vascular disease, diabetes, or hypertension(2). In the youngest participants (40-42 years), total plasma homocysteine concentrations in males (10.8 μmol/L) were 19 per cent higher than in females (9.1 μmol/L). Of 1,160 members of the original Framingham Heart Study cohort aged between 67-96 years, total plasma homocysteine concentrations were 10 per cent higher in males (11.8

μmol/L) than in females (10.7 μmol/L) for those aged less than 75 years(24). The present study also demonstrated higher plasma total homocysteine concentrations in males (11.495 μmol/L) than in females (8.547 μmol/L), the difference was 34.5 per cent. The reason for the higher homocysteine concentrations in males may be explained by differences in body size, estrogen status and vitamin status. Moreover, Brattstrom L *et al.* established the correlation between plasma homocysteine concentrations and serum creatinine(25). This association may indicate increased homocysteine production as a consequence of methyl group transfer during creatinine metabolism.

The homocysteine data from the present study present a unique opportunity to establish population reference ranges in a nationally representative sample of Thai subjects. In general, investigators




Fig. 1. Histograms of plasma total homocysteine concentrations by sex.

have recommended that reference ranges for total homocysteine concentrations should be established in populations with apparently adequate vitamin status. However, previously published references were based on various samples, for example the 97.5 percentile from a population-based sample of Norwegians was 12.6 μmol/L in females and 14.5 μmol/L in males aged between 40-42 years, and 14.5

μmol/L in females and 17.8 μmol/L in males aged between 65-67 years(26). Other investigators calculated 95 per cent reference intervals as the mean total homocysteine + 2 standard deviations from smaller convenience samples(27,28). Ubbink et al suggested a reference range of 4.9-11.7 μmol/L, which was calculated from the expected effects of vitamin supplementation in South African males aged




Fig. 2. Box plot of plasma total homocysteine concentrations compared between males and females.




Fig. 3. Bar chart of prevalence of hyperhomocysteinemia in males and females.

18-65 years(29). Rasmussen *et al* provided age-specific reference ranges based on vitamin-replete Danish males and females aged between 20-29 years to be 4.6-8.1 $\mu\text{mol/L}$, 4.5-7.9 $\mu\text{mol/L}$ for females

and 6.3-11.2 $\mu\text{mol/L}$ for males aged between 30-59 years, and 5.8-11.9 $\mu\text{mol/L}$ for males and females aged 60 years or older(30). Joosten *et al* reported a reference range of 5.3-12.7 $\mu\text{mol/L}$ for vitamin-

supplemented Belgian, German and Dutch participants aged between 65-95 years(28).

These data show that the prevalence of hyperhomocysteinemia in Thai males is common. However, a threshold of total homocysteine concentrations associated with an increased risk for cardiovascular disease has not been clearly established. Most studies suggested that homocysteine concen-

trations of 10-12.5 $\mu\text{mol/L}$ or higher are associated with a significantly increased risk of vascular disease (3,31,32). Moreover, Malinow et al reported an elevated risk of thickening of the carotid artery intimal media starting at total homocysteine concentrations as low as 8.3 $\mu\text{mol/L}$ (33). The limitation of the present study was, measured serum folate and vitamin B12 concentrations were not.

(Received for publication on November 22, 2001)

REFERENCES

1. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. *JAMA* 1995; 274: 1049-57.
2. Nygard O, Vollset SE, Refsum H, et al. Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. *JAMA* 1995; 274: 1526-33.
3. Graham IM, Daly LE, Refsum HM, et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. *JAMA* 1997; 277: 1775-81.
4. Aronow WS, Ahn C. Association between plasma homocysteine and coronary artery disease in older persons. *Am J Cardiol* 1997; 80: 1216-8.
5. Anderson JL, Muhlestein JB, Horne BD, et al. Plasma homocysteine predicts mortality independently of traditional risk factors and C-reactive protein in patients with angiographically defined coronary artery disease. *Circulation* 2000; 102: 1227-32.
6. Stampfer MJ, Malinow MR, Willett WC, et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. *JAMA* 1992; 268: 877-81.
7. Graham I. Homocysteine in health and disease. *Ann Intern Med* 1999; 131: 387-8.
8. Alfthan G, Aro A, Gey KF. Plasma homocysteine and cardiovascular disease mortality. *Lancet* 1997; 349: 397.
9. Pancharunti N, Lewis CA, Sauberlich HE, et al. Plasma homocyst(e)ine, folate, and vitamin B-12 concentrations and risk for early-onset coronary artery disease. *Am J Clin Nutr* 1994; 59: 940-8.
10. Wilcken DE, Wilcken B. B vitamins and homocysteine in cardiovascular disease and aging. *Ann N Y Acad Sci* 1998; 854: 361-70.
11. Leowattana W, Mahanonda N, Bhuripunyo K, Pokum S. Association between serum homocysteine, vitamin B12, folate and Thai coronary artery disease patients. *J Med Assoc Thai* 2000; 83: 536-42.
12. Welch GN, Upchurch GR, Jr, Farivar RS, et al. Homocysteine-induced nitric oxide production in vascular smooth-muscle cells by NF-kappa B-dependent transcriptional activation of Nos2. *Proc Assoc Am Physicians* 1998; 110: 22-31.
13. Kanani PM, Sinkey CA, Browning RL, Allaman M, Knapp HR, Haynes WG. Role of oxidant stress in endothelial dysfunction produced by experimental hyperhomocyst(e)inemia in humans. *Circulation* 1999; 100: 1161-8.
14. Chambers JC, Obeid OA, Refsum H, et al. Plasma homocysteine concentrations and risk of coronary heart disease in UK Indian Asian and European men. *Lancet* 2000; 355: 523-7.
15. Blundell G, Jones BG, Rose FA, Tudball N. Homocysteine mediated endothelial cell toxicity and its amelioration. *Atherosclerosis* 1996; 122: 163-72.
16. Dudman NP, Temple SE, Guo XW, Fu W, Perry MA. Homocysteine enhances neutrophil-endothelial interactions in both cultured human cells and rats *in vivo*. *Circ Res* 1999; 84: 409-16.
17. Whincup PH, Refsum H, Perry IJ, et al. Serum total homocysteine and coronary heart disease: Prospective study in middle aged men. *Heart* 1999; 82: 448-54.
18. Martyn CN. Serum homocysteine and risk of coronary heart disease in UK Indian Asians. *Lancet* 2000; 355: 512-3.
19. Voutilainen S, Lakka TA, Hamelahti P, Lehtimaki T, Poulsen HE, Salonen JT. Plasma total homocysteine concentration and the risk of acute coronary

events: the Kuopio Ischaemic Heart Disease Risk Factor Study. *J Intern Med* 2000; 248: 217-22.

20. Selhub J, Jacques PF, Bostom AG, Wilson PW, Rosenberg IH. Relationship between plasma homocysteine and vitamin status in the Framingham study population. Impact of folic acid fortification. *Publ Hlth Rev* 2000; 28: 117-45.

21. Saw SM, Yuan JM, Ong CN, et al. Genetic, dietary, and other lifestyle determinants of plasma homocysteine concentrations in middle-aged and older Chinese men and women in Singapore. *Am J Clin Nutr* 2001; 73: 232-9.

22. de Bree A, Verschuren WM, Blom HJ. Biological cardiovascular risk factors and plasma homocysteine levels in the general Dutch population. *Atherosclerosis* 2001; 154: 513-4.

23. Vollset SE, Refsum H, Tverdal A, et al. Plasma total homocysteine and cardiovascular and non-cardiovascular mortality: The Hordaland Homocysteine Study. *Am J Clin Nutr* 2001; 74: 130-6.

24. Selhub J, Jacques PF, Rosenberg IH, et al. Serum total homocysteine concentrations in the third National Health and Nutrition Examination Survey (1991-1994): Population reference ranges and contribution of vitamin status to high serum concentrations. *Ann Intern Med* 1999; 131: 331-9.

25. Brattstrom L. Homocysteine and heart disease in Indian Asians. *Lancet* 2000; 355: 2248-50.

26. Nygard O, Refsum H, Ueland PM, Vollset SE. Major lifestyle determinants of plasma total homocysteine distribution: The Hordaland Homocysteine Study. *Am J Clin Nutr* 1998; 67: 263-70.

27. Ubbink JB, Fehily AM, Pickering J, Elwood PC, Vermaak WJ. Homocysteine and ischaemic heart disease in the Caerphilly cohort. *Atherosclerosis* 1998; 140: 349-56.

28. Joosten E, Lesaffre E, Riezler R. Are different reference intervals for methylmalonic acid and total homocysteine necessary in elderly people? *Eur J Haematol* 1996; 57: 222-6.

29. Ubbink JB, Vermaak WJ, Delport R, van der Merwe A, Becker PJ, Potgieter H. Effective homocysteine metabolism may protect South African blacks against coronary heart disease. *Am J Clin Nutr* 1995; 62: 802-8.

30. Rasmussen K, Moller J, Lyngbak M, Pedersen AM, Dybkjaer L. Age- and gender-specific reference intervals for total homocysteine and methylmalonic acid in plasma before and after vitamin supplementation. *Clin Chem* 1996; 42: 630-6.

31. Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland PM, Shaper AG. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. *Lancet* 1995; 346: 1395-8.

32. Selhub J, Jacques PF, Bostom AG, et al. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. *N Engl J Med* 1995; 332: 286-91.

33. Malinow MR, Nieto FJ, Szklo M, Chambliss LE, Bond G. Carotid artery intimal-medial wall thickening and plasma homocyst(e)ine in asymptomatic adults. The Atherosclerosis Risk in Communities Study. *Circulation* 1993; 87: 1107-13.

ยุบติดการณ์ของภาวะโโซโนซีสทันในเลือดสูงในประชากรไทยสุขภาพดี

วัฒนา เลี้ยงวัฒนา, พ.บ.*, นิธิ มหานนท์, พ.บ.**,
เกียรติชัย ภรรบัญโญ, พ.บ.**, ศศิกานต์ โพธิ์ค้ำ, ว.บ.**

พบว่าระดับความเข้มข้นของโ去买เมซลทินในเลือดเป็นตัวบ่งชี้ที่ดีในการบอกถึงภาวะขาดไฟเลเชลและวิตามิน บี 12 นอกเหนือจากนั้นยังพบว่าการเพิ่มสูงขึ้นของระดับความเข้มข้นของโ去买เมซลทินในเลือดยังมีความสัมพันธ์กับการเพิ่มความเสี่ยง แห่งการเกิดโรคหลอดเลือดต่าง ๆ โดยเฉพาะอย่างยิ่งโรคหลอดเลือดหัวใจ จุดประสงค์ในการศึกษาวิจัยในครั้งนี้เพื่อให้ทราบ ค่าความเข้มข้นของโ去买เมซลทินในเลือดของประชากรไทยสุขภาพดีโดยเปรียบเทียบค่าตั้งกล่าวในช่วงอายุต่าง ๆ ตลอดจน เปรียบเทียบระหว่างเพศหญิงและเพศชาย คุณผู้วิจัยได้ทำการวัดระดับความเข้มข้นของโ去买เมซลทินในเลือดของพนักงานบริษัท ชินวัต ที่มีสุขภาพดีจำนวน 3,345 คน ประกอบด้วยผู้ชาย 1,133 คน ผู้หญิง 2,212 คน ช่วงอายุระหว่าง 20-65 ปี โดยใช้วิธีฟลูออเรสเซ็นท์โพลาริเซชั่นอัลฟูโนแอกซ์เจน (เอฟพีโอเอ) พบว่าค่าเฉลี่ยความเข้มข้นของโ去买เมซลทินในพลาสม่าของ เพศชายและเพศหญิงมีค่าเท่ากัน 11.495 และ 8.547 ไมโครโมล/ลิตร ตามลำดับ โดยพบว่าค่าตั้งกล่าวในเพศชายสูงกว่า ในเพศหญิงอย่างมีนัยสำคัญทางสถิติ ($p < 0.0001$) ถ้าเปรียบเทียบในแต่ละกลุ่มอายุก็พบว่าในทุกกลุ่มอายุค่าความเข้มข้น ของโ去买เมซลทินในเลือดเพศชายจะสูงกว่าในเพศหญิงอย่างชัดเจนแต่ถ้าเปรียบเทียบในเพศเดียวกันพบว่าไม่พบความแตกต่าง ระหว่างกลุ่มอายุต่าง ๆ เมื่อใช้ค่าสูงสุดที่ระดับ 12 ไมโครโมล/ลิตร เพื่อแยกภาวะโ去买เมซลทินในเลือดสูงออกจากภาวะปกติ พบว่าเพศชายมีผู้ที่มีระดับโ去买เมซลทินในเลือดสูงกว่า 12 ไมโครโมล/ลิตร ถึง 33.6 เปอร์เซ็นต์ ในขณะที่เพศหญิงพบเพียง 6.69 เปอร์เซ็นต์ คุณผู้วิจัยสรุปว่า อุบัติการณ์ของการเกิดภาวะโ去买เมซลทินในเลือดสูงพบได้บ่อยมากในประชากรเพศชาย และความมีการศึกษาเพิ่มเติมเพื่อแสดงให้ทราบว่าการเพิ่มสูงขึ้นของระดับโ去买เมซลทินในเลือดตั้งกล่าวมีความสัมพันธ์อย่างไรกับ ระดับของไฟเลเชล วิตามิน บี 12 และ วิตามิน บี 6 ในชั้นรุ่ม

คำสำคัญ : ไฮโนซีลทิน, โฟเลท, วิตามิน บี 12, อุบัติการณ์, ภาวะไฮโนซีลทินในเลือดสูง

วัฒนา เลือกวัฒนา, นิช มหานนท์,
เกียรติศัย ภริปัญญา, ศศิเกียรต์ โพธิ์คำ
ฯ หมายเหตุทางแพทย์ ฯ 2544; 84 (ฉบับ

* ภาควิชาพยาธิวิทยาคลินิก,

** สำนักงานศูนย์โรคหัวใจสมเด็จพระบรมราชินีนาถ, คณะแพทยศาสตร์ศิริราชพยาบาล, มหาวิทยาลัยมหิดล, กรุงเทพฯ ๑๐๗๐๐